MCID: PLY041
MIFTS: 57

Polymyositis

Categories: Bone diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Polymyositis

MalaCards integrated aliases for Polymyositis:

Name: Polymyositis 52 53 58 54 17 71 32

Characteristics:

Orphanet epidemiological data:

58
polymyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Argentina),1-9/100000 (Argentina),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Spain),1-9/1000000 (Sweden); Age of onset: Adult,Elderly; Age of death: adult;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare systemic and rhumatological diseases


Summaries for Polymyositis

NINDS : 53 Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body.  It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60.  Progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a seated position, lifting objects, or reaching overhead.  People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias.  In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus.  Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.

MalaCards based summary : Polymyositis is related to lymphoma, hodgkin, classic and retinal vascular disease. An important gene associated with Polymyositis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Tacrolimus and Infliximab have been mentioned in the context of this disorder. Affiliated tissues include lung, skeletal muscle and t cells, and related phenotypes are muscular hypotonia and elevated serum creatine kinase

NIH Rare Diseases : 52 Polymyositis is a type of inflammatory myopathy , which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. The muscles affected by polymyositis are the skeletal muscles (those involved with making movements) on both sides of the body. Although the disease can affect people of all ages, most cases are seen in adults between the ages of 31 and 60 years. The disease is more common among women and among black individuals. The exact cause of polymyositis is unknown. The disease shares many characteristics with autoimmune disorders , which occur when the immune system mistakenly attacks healthy body tissues . In some cases, the disease may be associated with viral infections , connective tissue disorders , or an increased risk for malignancies (cancer ). Diagnosis is based on a clinical examination that may include laboratory tests, imaging studies, electromyography , and a muscle biopsy . Although there is no cure for polymyositis, treatment with corticosteroids or immunosuppressants can improve muscle strength and function.

Wikipedia : 74 Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to... more...

Related Diseases for Polymyositis

Diseases in the Polymyositis family:

Juvenile Polymyositis

Diseases related to Polymyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 679)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 29.4 MIR30A MIR21 MIR155
2 retinal vascular disease 29.2 MIR30A MIR21 MIR146B
3 pulmonary fibrosis, idiopathic 29.1 MIR30A MIR214 MIR21 MIR130A
4 cerebrovascular disease 28.8 MIR221 MIR21 MIR132
5 inclusion body myositis 28.7 MIR222 MIR221 MIR214 MIR21 MIR155 MIR146B
6 pancreatic adenocarcinoma 28.6 MIR221 MIR210 MIR21 MIR155
7 ovarian disease 28.5 MIR30A MIR222 MIR21 MIR132
8 coronary heart disease 1 28.5 MIR222 MIR221 MIR155
9 eye disease 28.1 MIR30A MIR214 MIR210 MIR21 MIR146B
10 clear cell renal cell carcinoma 28.0 MIR30A MIR221 MIR210 MIR21 MIR155
11 renal cell carcinoma, nonpapillary 27.8 MIR30A MIR221 MIR214 MIR210 MIR21 MIR155
12 dermatomyositis 27.8 RN7SL1 MIR30A MIR222 MIR221 MIR214 MIR210
13 lymphoma, non-hodgkin, familial 27.7 MIR30A MIR222 MIR214 MIR21 MIR155 MIR146B
14 melanoma 27.7 MIR222 MIR221 MIR210 MIR199B MIR154 MIR127
15 myocardial infarction 27.7 MIR30A MIR221 MIR210 MIR21 MIR155
16 cervical cancer 27.7 MIR30A MIR214 MIR21 MIR155 MIR146B MIR132
17 pancreatic ductal adenocarcinoma 27.7 MIR222 MIR221 MIR210 MIR21 MIR155
18 leukemia, chronic lymphocytic 27.5 MIR30A MIR221 MIR214 MIR21 MIR155 MIR154
19 leukemia, acute lymphoblastic 27.3 MIR222 MIR221 MIR210 MIR21 MIR199B MIR155
20 connective tissue disease 27.3 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21
21 diffuse large b-cell lymphoma 27.0 MIR222 MIR221 MIR214 MIR210 MIR21 MIR155
22 intestinal disease 26.4 MIR30A MIR222 MIR221 MIR214 MIR21 MIR155
23 pancreatic cancer 26.3 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21
24 leukemia, acute myeloid 26.3 MIR30A MIR222 MIR221 MIR210 MIR21 MIR199B
25 hepatocellular carcinoma 26.3 MIR30A MIR222 MIR221 MIR214 MIR21 MIR199B
26 prostate cancer 26.3 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21
27 facioscapulohumeral muscular dystrophy 1 26.2 MIR222 MIR221 MIR214 MIR21 MIR199B MIR155
28 ovarian cancer 25.7 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21
29 muscular dystrophy, duchenne type 25.6 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21
30 miyoshi muscular dystrophy 1 25.2 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21
31 nemaline myopathy 25.2 MIR30A MIR222 MIR221 MIR214 MIR210 MIR199B
32 lung cancer 25.0 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21
33 juvenile polymyositis 12.6
34 myositis 12.0
35 mixed connective tissue disease 11.8
36 childhood type dermatomyositis 11.7
37 myopathy 11.7
38 systemic scleroderma 11.6
39 antisynthetase syndrome 11.5
40 myelopathy, htlv-1-associated 11.5
41 tropical spastic paraparesis 11.5
42 necrotizing autoimmune myopathy 11.5
43 retrovirus-associated myelopathy 11.2
44 interstitial lung disease 10.8
45 lung disease 10.8
46 autoimmune disease 10.6
47 dysphagia 10.6
48 scleroderma, familial progressive 10.5
49 myasthenia gravis 10.5
50 respiratory failure 10.5

Comorbidity relations with Polymyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Dermatomyositis Heart Disease
Hypertension, Essential Hypothyroidism
Osteoporosis Temporal Arteritis

Graphical network of the top 20 diseases related to Polymyositis:



Diseases related to Polymyositis

Symptoms & Phenotypes for Polymyositis

Human phenotypes related to Polymyositis:

58 31 (show all 43)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscular hypotonia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001252
2 elevated serum creatine kinase 58 31 hallmark (90%) Very frequent (99-80%) HP:0003236
3 emg abnormality 58 31 hallmark (90%) Very frequent (99-80%) HP:0003457
4 arthralgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002829
5 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
6 cough 58 31 hallmark (90%) Very frequent (99-80%) HP:0012735
7 elevated aldolase level 58 31 hallmark (90%) Very frequent (99-80%) HP:0012544
8 proximal muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0003701
9 abnormal muscle fiber morphology 31 hallmark (90%) HP:0004303
10 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
11 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
12 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
13 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
14 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
15 respiratory insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002093
16 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
17 constipation 58 31 frequent (33%) Frequent (79-30%) HP:0002019
18 interstitial pulmonary abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0006530
19 exertional dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002875
20 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
21 gastroesophageal reflux 58 31 occasional (7.5%) Occasional (29-5%) HP:0002020
22 gait disturbance 58 31 occasional (7.5%) Occasional (29-5%) HP:0001288
23 hypertrophic cardiomyopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001639
24 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
25 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
26 chondrocalcinosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000934
27 myocardial infarction 58 31 occasional (7.5%) Occasional (29-5%) HP:0001658
28 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
29 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
30 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
31 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
32 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
33 dilated cardiomyopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001644
34 reduced tendon reflexes 58 31 occasional (7.5%) Occasional (29-5%) HP:0001315
35 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
36 abnormal mitral valve morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001633
37 vasculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002633
38 breast carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0003002
39 abnormal atrioventricular conduction 58 31 occasional (7.5%) Occasional (29-5%) HP:0005150
40 abnormal renal tubule morphology 31 occasional (7.5%) HP:0000091
41 abnormality of the renal tubule 58 Occasional (29-5%)
42 abnormality of the voice 58 Occasional (29-5%)
43 abnormality of muscle fibers 58 Very frequent (99-80%)

Drugs & Therapeutics for Polymyositis

Drugs for Polymyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
2
Infliximab Approved Phase 2, Phase 3 170277-31-3
3
leucovorin Approved Phase 3 58-05-9 6006 143
4
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
5
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
6
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
7
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
9
tannic acid Approved Phase 2, Phase 3 1401-55-4
10
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
11 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
12
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
13
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
14
Alendronate Approved Phase 3 66376-36-1, 121268-17-5 2088
15
Ustekinumab Approved, Investigational Phase 3 815610-63-0
16
Abatacept Approved Phase 3 332348-12-6 10237
17
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
18
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
19
belimumab Approved Phase 2, Phase 3 356547-88-1 10451420 5957
20
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
24
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
25 Antimetabolites Phase 3
26 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
27 glucocorticoids Phase 2, Phase 3
28 Gastrointestinal Agents Phase 2, Phase 3
29 Vitamin B Complex Phase 3
30 Folic Acid Antagonists Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Folate Phase 3
33 Vitamin B9 Phase 3
34 Methylprednisolone Acetate Phase 2, Phase 3
35 abobotulinumtoxinA Phase 3
36 Botulinum Toxins Phase 3
37 Botulinum Toxins, Type A Phase 3
38 Cholinergic Agents Phase 3
39 Trace Elements Phase 3
40 Vitamins Phase 3
41 Hydroxycholecalciferols Phase 3
42 Nutrients Phase 3
43 Micronutrients Phase 3
44 Calciferol Phase 3
45 Antineoplastic Agents, Immunological Phase 2, Phase 3
46 Alkylating Agents Phase 2, Phase 3
47 Anti-Infective Agents Phase 2, Phase 3
48 Antiviral Agents Phase 2, Phase 3
49 Respiratory System Agents Phase 2, Phase 3
50 Antidotes Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Controlled Clinical Study of GB-0998 for the Steroid-resistant Polymyositis and Dermatomyositis Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
2 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
3 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
4 An Open-label Clinical Trial of the Combination Treatment of Tacrolimus and Corticosteroid in Polymyositis/Dermatomyositis Patients With Interstitial Pneumonitis, With Comparison Against Corticosteroid-treated Historical Controls Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
5 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
6 Effectiveness of Botulinum Toxin A Injection for the Treatment of Lateral Epicondylitis Unrelieved by Usual Medical Cares : A Double Blind Randomized Controlled Trial Versus Placebo Completed NCT00437762 Phase 3 Botulinum Toxin A Injection;Placebo injection
7 Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
8 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments Recruiting NCT03981744 Phase 3 Ustekinumab 6 mg/kg;Ustekinumab 90 mg;Placebo IV;Placebo SC
9 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Active, not recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
10 A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease Active, not recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
11 Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis Active, not recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
12 Clinical Trial of Oral Medication for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
13 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
14 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
15 Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
16 A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
17 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
18 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
19 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
20 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
21 A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
22 A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Recruiting NCT04033926 Phase 2 KZR-616;Placebo
23 An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study Recruiting NCT03465111 Phase 2 ACTH (adrenocorticotropic hormone) gel
24 Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy Not yet recruiting NCT04062019 Phase 2 Interleukin-2
25 A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Low-dose Interleukin-2 in Combination With Standard Therapy Compared to Standard Therapy Alone in Adults With Active Idiopathic Inflammatory Myopathy Not yet recruiting NCT04237987 Phase 2 Interleukin-2;ciclosporin and corticosteroid
26 A Multi-centre Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis Terminated NCT01801917 Phase 2 Placebo;BAF312
27 A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
28 Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases. Unknown status NCT00230204 Phase 1
29 A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
30 A Phase 1, Randomized, Blinded, Single-Dose, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Completed NCT02780674 Phase 1
31 Phase I, Open-label Study of Mycophenolate Mofetil In Systemic Sclerosis Completed NCT00433186 Phase 1 Mycophenolate Mofetil
32 A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Pulmonary Arterial Hypertension ALPHA Trial Recruiting NCT03145298 Phase 1
33 A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Active, not recruiting NCT03817424 Phase 1 VIB7734;Placebo
34 Acthar Dermatomyositis and Polymyositis Treatment Unknown status NCT01637064 Acthar
35 The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease Unknown status NCT03101397
36 Detection Of Anti-Double Stranded Deoxyribonucleic Acid Antibodies In Autoimmune Rheumatic Diseases: Comparison Between Immunofluorescence And Enzyme Immunoassay Unknown status NCT03303508
37 A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy Unknown status NCT00971828
38 Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia Unknown status NCT01482494
39 Microbiology and Clinical Outcome of Community Acquired Pneumonia and Health-Care-Associated Pneumonia in Taiwan: a Multi-Center Study Unknown status NCT00873522
40 Specified Drug Use-results Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis Completed NCT02159651 tacrolimus
41 Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy Completed NCT02880527
42 Transcriptome Analysis Through a Dedicated Macro-array and TcLandscape Repertoire Analysis for Diagnosis of Myositis. Completed NCT00213629
43 Hand Function, Health Related Quality of Life and Activity Performance in Patients With Polymyositis or Dermatomyositis. Completed NCT00866125
44 Resistance Exercise Reduces the Expression of Inflammation and Fibrosis Associated Genes in Autoimmune Myositis Patients Completed NCT00519103
45 Prevalence of Inflammatory Myopathies in Alsace Completed NCT02881450
46 Outcome of Muscle Function and Disease Activity in Patients With Recent Onset Polymyositis and Dermatomyositis - a 1-year Follow-up Register Study Completed NCT01813617 Immunosuppressive Agents
47 Genetic and Family Studies of Inherited Muscle Diseases Completed NCT00001331
48 Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx Completed NCT00001167
49 Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases Completed NCT00341679
50 Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies Completed NCT01432613

Search NIH Clinical Center for Polymyositis

Genetic Tests for Polymyositis

Anatomical Context for Polymyositis

MalaCards organs/tissues related to Polymyositis:

40
Lung, Skeletal Muscle, T Cells, Heart, Testes, Skin, Thyroid

Publications for Polymyositis

Articles related to Polymyositis:

(show top 50) (show all 5755)
# Title Authors PMID Year
1
Distinctive patterns of microRNA expression in primary muscular disorders. 46 61
17942673 2007
2
Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study. 52
28855175 2017
3
Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. 61 54
19953283 2010
4
Beware of 'normal' creatine kinase levels in HIV-associated polymyositis. 61 54
20459937 2010
5
Dysferlin deficiency treated like refractory polymyositis. 54 61
19730931 2010
6
A dual role for HSP90 and HSP70 in the inflammatory myopathies: from muscle fiber protection to active invasion by macrophages. 61 54
19758187 2009
7
Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. 61 54
19303320 2009
8
[An autopsied case of thoracic esophageal cancer with polymyositis]. 54 61
19498309 2009
9
[A case of chronic graft-versus-host disease presenting with polymyositis]. 54 61
19404011 2009
10
Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types. 54 61
19443969 2009
11
Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. 54 61
18276788 2008
12
Acute myopathy in a patient with oesophageal stricture. 61 54
17965038 2007
13
Rituximab for refractory polymyositis: an open-label prospective study. 54 61
17722224 2007
14
Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. 61 54
17420473 2007
15
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. 54 61
17265504 2007
16
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. 61 54
17207162 2007
17
Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. 54 61
16831829 2006
18
Expression of CCR7 and its ligands CCL19/CCL21 in muscles of polymyositis. 61 54
16887149 2006
19
Muscle inflammation, autoimmune Addison's disease and sarcoidosis in a patient with dysferlin deficiency. 54 61
16483775 2006
20
Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. 54 61
16431335 2006
21
Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. 54 61
16846524 2006
22
Chemokine receptor CCR7 is expressed in muscle fibers in juvenile dermatomyositis. 54 61
15950936 2005
23
Changes of single fiber electromyography in patients with inflammatory myopathies. 61 54
15844301 2005
24
The electromyographic features of acute rhabdomyolysis. 61 54
19078759 2005
25
[A study of vascular factor in the pathogenesis of polymyositis]. 54 61
15840223 2005
26
The prion protein in human neuromuscular diseases. 54 61
15476279 2004
27
Immunolocalization of protectin (CD59) and macrophages in polymyositis and dermatomyositis. 61 54
15020079 2004
28
Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. 54 61
17143695 2004
29
Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. 54 61
14512171 2003
30
Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. 54 61
12937135 2003
31
S-protein is expressed in necrotic fibers in Duchenne muscular dystrophy and polymyositis. 61 54
12707977 2003
32
Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. 54 61
12667656 2003
33
Relationship between utrophin and regenerating muscle fibers in duchenne muscular dystrophy. 54 61
12619170 2003
34
Expression of the costimulatory molecule BB-1 and its receptors in patients with scleroderma-polymyositis overlap syndrome. 61 54
12409186 2002
35
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. 54 61
12421999 2002
36
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. 54 61
12235211 2002
37
Overview of neuromuscular disorders affecting respiratory function. 54 61
16088611 2002
38
Recurrent acute myositis after allogeneic bone marrow transplantation for myelodysplasia. 61 54
12186701 2002
39
Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. 61 54
11953983 2002
40
Women with pregnancy-related polymyositis and high serum CK levels in the newborn. 61 54
11839858 2002
41
Serum levels of interleukin 15 in patients with rheumatic diseases. 54 61
11708407 2001
42
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases. 61 54
17039165 2001
43
Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. 54 61
11282091 2001
44
Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy. 61 54
11303793 2001
45
Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis. 61 54
11182151 2001
46
Increased interleukin-17 production in patients with systemic sclerosis. 54 61
11083268 2000
47
Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis. 54 61
10951151 2000
48
Expression of human IAP-like protein in skeletal muscle: a possible explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies. 61 54
10814776 2000
49
Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. 61 54
10843719 2000
50
AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. 61 54
10720271 2000

Variations for Polymyositis

Expression for Polymyositis

Search GEO for disease gene expression data for Polymyositis.

Pathways for Polymyositis

Pathways related to Polymyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21
2 11.43 MIR21 MIR199B MIR132 MIR127
3 11.42 MIR30A MIR132 MIR127
4 11.13 MIR222 MIR221 MIR210
5 10.91 MIR222 MIR221 MIR146B

GO Terms for Polymyositis

Cellular components related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.43 MIR30A MIR222 MIR221 MIR214 MIR21 MIR130A
2 extracellular space GO:0005615 9.36 MIR30A MIR222 MIR221 MIR210 MIR21 MIR199B

Biological processes related to Polymyositis according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 MIR30A MIR21 MIR155 MIR154 MIR132
2 negative regulation of apoptotic process GO:0043066 9.99 MIR30A MIR222 MIR221 MIR21
3 negative regulation of gene expression GO:0010629 9.95 MIR214 MIR21 MIR155 MIR154 MIR132
4 positive regulation of protein kinase B signaling GO:0051897 9.91 MIR222 MIR221 MIR21 MIR199B MIR132
5 negative regulation of inflammatory response GO:0050728 9.84 MIR222 MIR221 MIR155
6 negative regulation of angiogenesis GO:0016525 9.83 MIR222 MIR214 MIR21
7 positive regulation of blood vessel endothelial cell migration GO:0043536 9.79 MIR30A MIR221 MIR210
8 positive regulation of epithelial to mesenchymal transition GO:0010718 9.78 MIR222 MIR221 MIR21
9 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.75 MIR222 MIR221 MIR155
10 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.73 MIR221 MIR199B MIR155 MIR146B
11 positive regulation of angiogenesis GO:0045766 9.73 MIR30A MIR210 MIR21 MIR199B MIR132 MIR130A
12 positive regulation of vascular endothelial cell proliferation GO:1905564 9.71 MIR21 MIR132 MIR130A
13 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.71 MIR30A MIR222 MIR221 MIR214
14 positive regulation of cardiac muscle cell proliferation GO:0060045 9.7 MIR222 MIR199B
15 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.7 MIR21 MIR199B
16 positive regulation of epithelial cell migration GO:0010634 9.7 MIR222 MIR221
17 negative regulation of necroptotic process GO:0060546 9.7 MIR221 MIR214 MIR155
18 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.69 MIR21 MIR132
19 positive regulation of erythrocyte differentiation GO:0045648 9.69 MIR222 MIR221
20 cellular response to virus GO:0098586 9.68 MIR21 MIR130A
21 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.68 MIR222 MIR155
22 positive regulation of activated T cell proliferation GO:0042104 9.68 MIR21 MIR155
23 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.68 MIR221 MIR21
24 positive regulation of cardiac muscle hypertrophy GO:0010613 9.67 MIR21 MIR155
25 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.67 MIR21 MIR132
26 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.67 MIR214 MIR21
27 negative regulation of cell adhesion molecule production GO:0060354 9.67 MIR222 MIR221 MIR155
28 negative regulation of innate immune response GO:0045824 9.66 MIR21 MIR155
29 positive regulation of endothelial cell differentiation GO:0045603 9.65 MIR21 MIR199B
30 positive regulation of connective tissue replacement GO:1905205 9.65 MIR214 MIR155
31 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.65 MIR222 MIR221 MIR155
32 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.64 MIR214 MIR155
33 positive regulation of axon regeneration GO:0048680 9.64 MIR222 MIR221
34 negative regulation of interleukin-8 production GO:0032717 9.63 MIR155 MIR132
35 negative regulation of regulatory T cell differentiation GO:0045590 9.63 MIR21 MIR155
36 negative regulation by host of viral genome replication GO:0044828 9.63 MIR222 MIR221 MIR155
37 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.62 MIR210 MIR21
38 positive regulation of vascular smooth muscle cell dedifferentiation GO:1905176 9.6 MIR221 MIR214
39 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.59 MIR222 MIR221
40 positive regulation of Schwann cell migration GO:1900149 9.58 MIR222 MIR221
41 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.57 MIR222 MIR221
42 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.56 MIR222 MIR221
43 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.55 MIR222 MIR221 MIR214 MIR21 MIR130A
44 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.54 MIR222 MIR221 MIR21
45 negative regulation of interleukin-21 production GO:0032705 9.5 MIR222 MIR221 MIR21
46 miRNA mediated inhibition of translation GO:0035278 9.5 MIR30A MIR222 MIR221 MIR210 MIR21 MIR155
47 gene silencing by miRNA GO:0035195 9.44 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21

Molecular functions related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR30A MIR222 MIR221 MIR214 MIR210 MIR21

Sources for Polymyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....